Roche Holding AG (XSWX:RO) Other Operating Expense: CHF-278 Mil (TTM As of Dec. 2025)


XSWX:RO Roche Holding AG XSWX:RO
77 GF Score
Price CHF339.20
GF Value CHF269.42
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Roche Holding AG Other Operating Expense?

Roche Holding AG XSWX:RO -1.45% 77 Other Operating Expense is CHF-278 Mil as of Dec. 2025. GuruFocus rates XSWX:RO with a GF Score™ of 77/100 and a GF Value™ of CHF269.42 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Roche Holding AG's Other Operating Expense for the six months ended in Dec. 2025 was CHF-37 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-278 Mil.

Roche Holding AG's quarterly Other Operating Expense declined from Dec. 2024 (CHF2,920 Mil) to Jun. 2025 (CHF-241 Mil) but then increased from Jun. 2025 (CHF-241 Mil) to Dec. 2025 (CHF-37 Mil).

Roche Holding AG's annual Other Operating Expense increased from Dec. 2023 (CHF-392 Mil) to Dec. 2024 (CHF2,495 Mil) but then declined from Dec. 2024 (CHF2,495 Mil) to Dec. 2025 (CHF-278 Mil).

Roche Holding AG Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Roche Holding AG's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roche Holding AG Other Operating Expense Chart

Roche Holding AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3,049.00 -825.00 -392.00 2,495.00 -278.00

Roche Holding AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 455.00 -425.00 2,920.00 -241.00 -37.00
XSWX:RO
77GF Score
Roche Holding AG XSWX:RO
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Roche Holding AG Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF-278 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of CHF-278 Mil mean?
Roche Holding AG (XSWX:RO) has a Other Operating Expense of CHF-278 Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on Roche Holding AG and its competitors.
Is Roche Holding AG's Other Operating Expense too high?
Roche Holding AG's current Other Operating Expense is CHF-278 Mil. Overall, Roche Holding AG has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roche Holding AG's Other Operating Expense compare to LLY and JNJ?
Roche Holding AG's Other Operating Expense of CHF-278 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Drug Manufacturers company?
A good Other Operating Expense depends on the Drug Manufacturers industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Roche Holding AG and its competitors. Roche Holding AG's current Other Operating Expense is CHF-278 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roche Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Roche Holding AG (XSWX:RO) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF269.42, compared to a current price of CHF339.20 — trading 25.9% above its estimated fair value. The current Other Operating Expense is CHF-278 Mil. Roche Holding AG's overall GF Score™ is 77/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Roche Holding AG (XSWX:RO), the current Other Operating Expense is CHF-278 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Roche Holding AG (XSWX:RO) Overvalued in 2026?

Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued. The current stock price of CHF339.20 is trading 25.9% above its estimated GF Value™ of CHF269.42. GuruFocus considers Roche Holding AG to be Modestly Overvalued.

Key valuation signals for XSWX:RO:

  • Other Operating Expense: CHF-278 Mil
  • GF Value™: CHF269.42 vs. price of CHF339.20 (25.9% above fair value)
  • GF Score™: 77/100 with 7 warning signs

No single metric tells the full story. See the XSWX:RO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Roche Holding AG Business Description

Address Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
77GF Score

Get the complete analysis for XSWX:RO

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF339.20
Price
CHF269.42
GF Value